### Alert
Hypertension may recur after cessation.
Neonatal abstinence syndrome may recur after cessation.
Evidence is insufficient to assess the efficacy and safety of clonidine for sedation and analgesia in term and preterm newborn infants receiving mechanical ventilation.

### Indication
- Sedation
- Hypertension
- Neonatal abstinence syndrome

### Action
Clonidine is an α2-agonist used to produce reduction in blood pressure and sedation.
Compared with dexmedetomidine, clonidine has a lower selectivity for α2-receptors (α1:α2 ratio of 1:1620 for dexmedetomidine versus 1:220 for clonidine). As central α2 effects are sedative, clonidine is less sedating than dexmedetomidine. [1]

### Drug type
Sedative, hypnotic. Centrally acting α2-agonist.

### Trade name
- Catapres Ampoules
- MZ Clonidine HCl Injection
- APO-Clonidine Tablets
- Catapres 100 Tablets
- Catapres 150 Tablets
- Oral solution or suspension: Compounded by pharmacy in-house (check which strength is stocked with Pharmacy Department).

### Presentation
**IV preparations:**
150 microgram/mL ampoule

**Oral preparations:**
100 microgram/tablet, 150 microgram/tablet
Solution or suspension: Compounded by pharmacy in-house (check which strength is stocked with Pharmacy Department).
IV clonidine (ampoule) may be given orally either neat or diluted with water prior to administration to give a suitable dose volume.

### Dosage/Interval
**Sedation:**
- IV: Loading dose of 0.5 to 1 microgram/kg over 15 minutes followed by a continuous infusion of 0.2 microgram/kg/hour and titrate up to a maximum of 1 microgram/kg/hour in hemodynamically stable neonates. [2]
- ORAL: 1 microgram/kg/dose 8 hourly and titrate it up to a maximum 2 micrograms/kg/dose 6 hourly. [2, 3] [Group consensus]

**Acute severe hypertension:**
10 microgram/kg infused over 4 hours. Additional dose of 5 microgram/kg may be given. [4] Consider continuous intra-arterial monitoring.

**Chronic hypertension:**
- Oral: 0.5 to 2.5 microgram/kg/dose 6 to 8 hourly. [5, 6]

**Neonatal abstinence syndrome:**
Initial therapy: 5 microgram/kg/day divided in 6 to 8 doses (oral recommended).
Increase dose by 25% every 24 hours to a maximum 12 microgram/kg/day according to neonatal abstinence syndrome scores. [7]

**Weaning/ceasing clonidine:**
If a neonate has received regular clonidine for >5 days, the dose should be weaned by about 50% each day for 2 to 3 days (reflecting an average half-life of 17 hours in neonates) before ceasing the drug. Watch for tachycardia, hypertension, sweating, agitation, but remember these may also be opioid withdrawal symptoms.
Intravenous clonidine can be converted to oral/nasogastric route when requirements are less than 0.75 microgram/kg/hour. The same daily dose is divided into 3 doses for 8 hourly administration (i.e. 4 to 6 microgram/kg orally every 8 hours). [Group consensus]

**Dose adjustments**
- Therapeutic hypothermia: no information.
- ECMO: no information.
- Renal: commence on a low dose in infants with renal impairment and adjust according to response.
- Hepatic: not applicable.

**Maximum dose**
- Neonatal abstinence syndrome: 12 microgram/kg/day. [7]
- Hypertension: 25 microgram/kg/day has been reported. However, it is recommended to use in combination with other antihypertensive agents rather than at higher dose as a single agent. [2]

**Total cumulative dose**
- **Route**
  - IV
  - Oral

**Preparation**
- **IV:**
  - Step 1:
    - Draw up 1 mL (150 micrograms) of Clonidine and add to 4 mL of Normal Saline 0.9% to make a final volume of 5 mL with a concentration of 150 microgram/5mL or 30microgram/mL.

  - Step 2:
    - From the above solution draw up 1.66 mL/kg (50 microgram/kg) and further dilute with sodium chloride 0.9% to make a final volume of 50 mL with a concentration of 1 mL/hour = 1 microgram/kg/hour.

- **Oral:**
  - Tablet: Disperse 100 microgram tablet in 20 mL sterile water. Tablet will disperse within 2 minutes. Shake or stir until an even dispersion is formed and then measure the required dose immediately. IV clonidine (ampoule) may be given orally as either neat or diluted with water prior to administration to give a suitable dose volume.
  - Solution or suspension: Compounded by pharmacy in-house (check which strength is stocked with Pharmacy Department).

**Administration**
- IV infusion.
  - Use a dedicated infusion line to avoid boluses.

**Monitoring**
- Neonatal abstinence syndrome: monitor Neonatal Abstinence Syndrome scores, cardiorespiratory observations and intermittent blood pressure.
- Sedation of infants on mechanical ventilation: continuous electrocardiogram (ECG) and/or oxygen saturation and continuous or intermittent blood pressure, pain and comfort scores.
- Hypertension: For initial treatment, continuous ECG and/or oxygen saturation, and continuous or intermittent blood pressure monitoring.

**Contraindications**
- Hypersensitivity to the drug.
- Heart block or severe ventricular dysfunction.

**Precautions**
- Rebound hypertension may occur after cessation.
- Rebound neonatal abstinence syndrome may occur after cessation.
- May need to reduce dose in infants with renal impairment.

**Drug interactions**
- Clonidine will enhance the effects of anaesthetics, sedatives, hypnotics and opioids.
- Clonidine will interact with other hypertensives; NSAIDs; α2-adrenergic blockers eg phentolamine; β-blockers; digitalis glycosides; tricyclic antidepressants; and α-blocking neuroleptics.

**Adverse reactions**
- Hypotension, bradycardia, rebound hypertension, somnolence and xerostomia. [5]

**Compatibility**
- Fluids: Sodium chloride 0.9%.
CLONIDINE
Newborn use only

Y-site: aminophylline, dobutamine, dopamine, epinephrine, fentanyl, heparin, ketamine, labetalol, lignocaine, lorazepam, magnesium sulphate, methadone, morphine HCl, glyceryl trinitrate, norepinephrine, potassium chloride.

Incompatibility
Y-site: midazolam, verapamil

Stability
Tablet dispersed in water: make a fresh solution for each dose and use immediately.
Check with Pharmacy Department for compounded oral suspension or solution.

Storage
Ampoule: Store below 25°C. Protect from light.
Tablet: Store below 25°C.
Check with Pharmacy Department for compounded oral suspension or solution.

Excipients
Ampoule: Sodium chloride, hydrochloric acid and water for injections.
Catapres Tablet: Maize starch, lactose monohydrate, calcium hydrogen phosphate, colloidal anhydrous silica, povidone and stearic acid.
APO-Clonidine Tablet: Allura Red AC, hypromelose, microcrystalline cellulose, magnesium stearate, maize starch, lactose monohydrate, calcium hydrogen phosphate, colloidal anhydrous silica.
Check with Pharmacy Department for compounded oral suspension or solution.

Special comments
Evidence
Refer to full version.

Practice points
Neonatal abstinence syndrome: The optimal regimen to manage symptomatic NAS is unclear. [15] In infants with NAS secondary to opioid withdrawal, clonidine 5 microgram/kg/day up to a maximum 12 microgram/kg/day in 6-8 divided doses may reduce need for morphine treatment and duration of treatment. [7] [LOE II, GOR C]
Sedation: Evidence is insufficient to show the efficacy and safety of clonidine for sedation and analgesia in term and preterm newborn infants receiving mechanical ventilation. [8] [LOE II GOR D]
Chronic hypertension: Recommend to use at lower doses (2–10 µg/kg/day) in 3 or 4 divided doses) in combination with other antihypertensive agents rather than at higher dose as a single agent.

References
Refer to full version.

VERSION/NUMBER 0.1
DATE
Original
28/05/2020
REVIEW (5 years)
28/05/2025

Authors Contribution
Original author/s
Assoc Prof David Osborn, Dr Srinivas Bolisetty
Evidence Review
Assoc Prof David Osborn
Expert review
Dr David Schell, Dr Hari Ravindranathan
Nursing Review
Ms Eszter Jozsa, Ms Kirsty Minter
Pharmacy Review
Ms Cindy Chen
ANMF Group contributors
Dr Srinivas Bolisetty, Dr Himanshu Popat, Dr Nilkant Phad, Ms Carmen Burman, Ms Thao Tran, Ms Emily Do, Ms Wendy Huynh
Final editing and review of the original
Dr Srinivas Bolisetty, Assoc Prof David Osborn, Ms Cindy Chen
Electronic version
Dr Ian Callander, Ms Cindy Chen
Facilitator
Dr Srinivas Bolisetty

This is a printed copy. Please refer to the HNE health PPG for the most up to date version.